Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib

Catherine C Mitchell, Omi A Parikh Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire, UK Abstract: The last decade has seen a surge in the treatment options for metastatic renal cell carcinoma and life expectancies are now approaching 3 years from diagnosis. There is some sug...

Full description

Bibliographic Details
Main Authors:	Mitchell CC, Parikh OA
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-04-01
Series:	Patient Preference and Adherence
Online Access:	http://www.dovepress.com/factors-involved-in-treatment-preference-in-patients-with-renal-cancer-a16535

Similar Items

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
by: Jordan Amdahl, et al.
Published: (2017-01-01)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
by: Ridhima Iyer, et al.
Published: (2017-01-01)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
by: Xinan Sheng, et al.
Published: (2020-03-01)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2018-10-01)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
by: Que Y, et al.
Published: (2018-07-01)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
by: Joshua M. Lang, et al.
Published: (2010-01-01)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
by: Pedro Isaacsson Velho, et al.
Published: (2018-09-01)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2019-03-01)

Pazopanib in the treatment of advanced renal cell carcinoma
by: M. I. Volkova, et al.
Published: (2018-11-01)

Pazopanib in the treatment of advanced renal cell carcinoma
by: David Cella, et al.
Published: (2016-02-01)

Custo-efetividade do pazopanibe comparado ao sunitinibe para câncer renal metastático na perspectiva de um hospital do Sistema Único de Saúde
by: Isandra Oliveira Meirelles, et al.

Imbalance of Hypoxia-Inducible Factors Involved in the Drug Resistance of Sunitinib treatment in Renal Cell Carcinoma
by: Liu, Shu-Yu, et al.
Published: (2012)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
by: William L. Read, et al.
Published: (2016-10-01)

Sunitinib for advanced renal cell cancer
by: Chris Coppin
Published: (2008-03-01)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
by: Bukowski RM
Published: (2011-08-01)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
by: Sabrina Rossetti, et al.
Published: (2017-07-01)

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
by: Ivana Puliafito, et al.
Published: (2020-01-01)

Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
by: Huan Deng, et al.
Published: (2019-05-01)

Sunitinib in the treatment of metastatic renal cell carcinoma
by: Thomas A. Schmid, et al.
Published: (2016-12-01)

The prospects of pazopanib in advanced renal cell carcinoma
by: Shilpa Gupta, et al.
Published: (2013-10-01)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
by: C Lance Cowey, et al.
Published: (2010-09-01)

Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
by: Rafael Corrêa Coelho, et al.

Experience with sunitinib in the treatment of metastatic renal cell carcinoma
by: Manuela Schmidinger, et al.
Published: (2012-10-01)

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
by: Marjut Niinivirta, et al.
Published: (2020-04-01)

Which patients with renal cancer may benefit from sunitinib therapy?
by: Tom Ferguson, et al.
Published: (2010-03-01)

A Case of Cardiac Tamponade in a Patient with Metastatic Renal Cell Carcinoma on Pazopanib Treatment
by: Vinu Sarathy, et al.
Published: (2020-01-01)

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
by: Rafia S. Al-Lamki, et al.
Published: (2020-04-01)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
by: Teresa Di Desidero, et al.
Published: (2019-11-01)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
by: Naveen S. Vasudev, et al.
Published: (2011-01-01)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
by: Naveen S. Vasudev, et al.
Published: (2011-10-01)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
by: Çetin Ordu, et al.
Published: (2016-06-01)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient
by: Camillo Porta, et al.
Published: (2017-06-01)

Pazopanib for the treatment of soft-tissue sarcoma
by: Heudel P, et al.
Published: (2012-10-01)

Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer
by: Davidson BA, et al.
Published: (2014-03-01)

Sunitinib efficacy in patients with disseminated renal cell carcinoma
by: O. B. Karyakin, et al.
Published: (2020-02-01)

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
by: Theofanis Vasileiadis, et al.
Published: (2019-04-01)

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence
by: Mimma Rizzo, et al.
Published: (2017-08-01)

Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01)